NHS England’s Plans to Optimize Cost-Effectiveness of New Weight Loss Drugs, Including Phased 12-Year Model for Mounjaro
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
$2995
National Health Service (NHS) England has pioneered a novel 12-year trial scheme to help ensure cost-effective reimbursement of Eli Lilly's (US) innovative weight loss drug Mounjaro (tirzepatide) to NHS patients, by prioritizing those most in need and evaluating several possible provision models in parallel in patients with the greatest need before expanding to a broader population.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
See what our customers are saying
Related reports
View more Obesity reports
New
New
New